Quality of Life in Chronic Venous Disease: Bridging the Gap Between Patients and Physicians.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 3, doi. 10.1007/s40261-023-01264-9
- By:
- Publication type:
- Article
Works matching IS 11732563 AND DT 2023 AND VI 43 AND IP 1
Results: 15
1
2
Optimising Decision Making in Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 15, doi. 10.1007/s40261-023-01263-w
- By:
- Publication type:
- Article
3
Foreword.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 1, doi. 10.1007/s40261-023-01262-x
- By:
- Publication type:
- Article
4
Improving Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction: New Evidence from Clinical Trials to Real Life.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 9, doi. 10.1007/s40261-023-01261-y
- By:
- Publication type:
- Article
5
Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 37, doi. 10.1007/s40261-022-01232-9
- By:
- Publication type:
- Article
6
Correction to: Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
7
Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 13, doi. 10.1007/s40261-022-01231-w
- By:
- Publication type:
- Article
8
Gastric Glitch: A New Functional Disease Treated with Buspirone and Prucalopride in an N-of-1 Double-Blind Clinical Trial.
- Published in:
- 2023
- By:
- Publication type:
- Letter
9
Long-Term Safety and Effectiveness of Erenumab in Patients with Migraine: A Systematic Review and Single-Arm Meta-analysis.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 45, doi. 10.1007/s40261-022-01230-x
- By:
- Publication type:
- Article
10
CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study).
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 61, doi. 10.1007/s40261-022-01226-7
- By:
- Publication type:
- Article
11
Correction to: Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
12
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
- Published in:
- 2023
- By:
- Publication type:
- Letter
13
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
- Published in:
- 2023
- By:
- Publication type:
- Letter
14
Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 1, doi. 10.1007/s40261-022-01229-4
- By:
- Publication type:
- Article
15
Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 1, p. 23, doi. 10.1007/s40261-022-01204-z
- By:
- Publication type:
- Article